Your browser doesn't support javascript.
loading
Integrating in vitro metabolomics with a 96-well high-throughput screening platform.
Malinowska, Julia M; Palosaari, Taina; Sund, Jukka; Carpi, Donatella; Bouhifd, Mounir; Weber, Ralf J M; Whelan, Maurice; Viant, Mark R.
Afiliação
  • Malinowska JM; School of Biosciences, University of Birmingham, Birmingham, B15 2TT, UK.
  • Palosaari T; European Commission, Joint Research Centre (JRC), 21027, Ispra, Italy.
  • Sund J; European Commission, Joint Research Centre (JRC), 21027, Ispra, Italy.
  • Carpi D; European Commission, Joint Research Centre (JRC), 21027, Ispra, Italy.
  • Bouhifd M; European Commission, Joint Research Centre (JRC), 21027, Ispra, Italy.
  • Weber RJM; European Chemicals Agency, Helsinki, Finland.
  • Whelan M; School of Biosciences, University of Birmingham, Birmingham, B15 2TT, UK.
  • Viant MR; Phenome Centre Birmingham, University of Birmingham, Birmingham, B15 2TT, UK.
Metabolomics ; 18(1): 11, 2022 01 09.
Article em En | MEDLINE | ID: mdl-35000038
INTRODUCTION: High-throughput screening (HTS) is emerging as an approach to support decision-making in chemical safety assessments. In parallel, in vitro metabolomics is a promising approach that can help accelerate the transition from animal models to high-throughput cell-based models in toxicity testing. OBJECTIVE: In this study we establish and evaluate a high-throughput metabolomics workflow that is compatible with a 96-well HTS platform employing 50,000 hepatocytes of HepaRG per well. METHODS: Low biomass cell samples were extracted for metabolomics analyses using a newly established semi-automated protocol, and the intracellular metabolites were analysed using a high-resolution spectral-stitching nanoelectrospray direct infusion mass spectrometry (nESI-DIMS) method that was modified for low sample biomass. RESULTS: The method was assessed with respect to sensitivity and repeatability of the entire workflow from cell culturing and sampling to measurement of the metabolic phenotype, demonstrating sufficient sensitivity (> 3000 features in hepatocyte extracts) and intra- and inter-plate repeatability for polar nESI-DIMS assays (median relative standard deviation < 30%). The assays were employed for a proof-of-principle toxicological study with a model toxicant, cadmium chloride, revealing changes in the metabolome across five sampling times in the 48-h exposure period. To allow the option for lipidomics analyses, the solvent system was extended by establishing separate extraction methods for polar metabolites and lipids. CONCLUSIONS: Experimental, analytical and informatics workflows reported here met pre-defined criteria in terms of sensitivity, repeatability and ability to detect metabolome changes induced by a toxicant and are ready for application in metabolomics-driven toxicity testing to complement HTS assays.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Metabolômica / Ensaios de Triagem em Larga Escala Tipo de estudo: Diagnostic_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Limite: Animals Idioma: En Revista: Metabolomics Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Metabolômica / Ensaios de Triagem em Larga Escala Tipo de estudo: Diagnostic_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Limite: Animals Idioma: En Revista: Metabolomics Ano de publicação: 2022 Tipo de documento: Article